Medindia

X

ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference

Thursday, September 17, 2009 General News J E 4
Advertisement
MARKHAM, ON, Sept. 3 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, today announced that it is scheduled to make an investor presentation at the Rodman Renshaw Annual Global Investment Conference at 2:25 pm EDT on Friday, September 11, 2009. The conference will be held at the New York Palace Hotel, September 9-11, 2009.

AlphaRx will make its presentation in the Spellman Salon (5th Floor) and a live webcast of the presentation will be available via a link provided at http://www.wsw.com/webcast/rrshq15/alrx . An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. For more information, please visit www.AlphaRx.com.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

SOURCE AlphaRx Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Shire Announces FDA Approval of Once-Daily INTUNIV...
S
MDS to Release Third Quarter 2009 Financial Result...